伊沙妥昔单抗治疗复发和/或难治性AL淀粉样变性:前瞻性2期试验(SWOG S1702)结果
这项多中心协作组2期试验评估伊沙妥昔单抗单药治疗复发AL淀粉样变性的血液学缓解、器官缓解和安全性。43例患者注册,35例可评估疗效,总体血液学缓解率77.1%,57%达非常好的部分缓解及以上,中位至部分缓解时间1.1个月。
要点
- 伊沙妥昔单抗单药治疗复发AL淀粉样变性总体血液学缓解率77.1%。
- 57%患者达非常好的部分缓解及以上,中位至部分缓解时间1.1个月。
- 肾脏缓解率50%(7/14),心脏缓解率57%(8/14)。
核心结论
- 伊沙妥昔单抗在既往治疗的AL淀粉样变性患者中显示出显著疗效,并具有良好的安全性。
研究设计与样本
- 多中心协作组2期试验,评估伊沙妥昔单抗单药治疗复发AL淀粉样变性的血液学缓解、器官缓解和安全性。
- 43例患者注册,35例可评估疗效。
- 伊沙妥昔单抗20 mg/kg静脉给药,第一个28天周期每周一次,第2至24周期每两周一次。
主要发现
- 总体血液学缓解率为77.1%,57%的患者达到非常好的部分缓解(VGPR)或更好。
- 中位至部分缓解(PR)或更好的时间为1.1个月。
- 肾脏缓解发生于50%(7/14)有肾脏受累的患者,心脏缓解发生于57%(8/14)有心脏受累且可评估的患者。
- 最常见的治疗相关≥3级不良事件包括淋巴细胞减少(n=3,8.5%)和感染(n=2,6%)。
关键数值与推荐
- 总体血液学缓解率77.1%,57%达VGPR或更好,中位至PR或更好时间1.1个月。
- 肾脏缓解率50%(7/14),心脏缓解率57%(8/14)。
- 治疗相关≥3级淋巴细胞减少n=3(8.5%),感染n=2(6%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Isatuximab is an immunoglobulin G1κ monoclonal antibody that binds with high affinity to CD38 expressed on plasma cells. Anti-CD38 antibodies have shown efficacy as monotherapy and in combination in a variety of settings for patients with multiple myeloma and light chain (AL) amyloidosis. This multicenter, cooperative group phase 2 trial was designed to evaluate hematologic response, organ response, and safety of isatuximab monotherapy for the treatment of relapsed AL amyloidosis. Isatuximab at 20 mg/kg was administered IV weekly during the first 28-day cycle, and then every other week during cycles 2 to 24. Forty-three patients were registered, with 35 patients being evaluable for response. The overall hematologic response rate was 77.1%, with 57% of patients achieving a very good partial response (VGPR) or better. The median time to partial response (PR) or better was 1.1 months. Renal response occurred in 50% (7/14) of patients with renal involvement, and cardiac response occurred in 57% (8/14) of patients who were evaluable utilizing N-terminal pro b-type natriuretic peptide (NT-proBNP) with cardiac involvement. The most common treatment-related grade ≥3 adverse events included lymphopenia (n = 3, 8.5%) and infection (n = 2, 6%). Isatuximab demonstrated substantial efficacy in previously treated patients with AL amyloidosis, and was associated with a good safety profile. This trial was registered at www.clinicaltrials.gov as #NCT03499808.
引用
- Parker TL, Rosenthal A, Sanchorawala V, et al. Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702). Blood. 2025. PMID: 40925099. doi:10.1182/blood.2024027962
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。